Larimar Therapeutics Stock Price Prediction

LRMR Stock  USD 6.16  0.03  0.49%   
The RSI of Larimar Therapeutics' the stock price is slightly above 65. This indicates that the stock is rather overbought by investors as of today. The main point of the Relative Strength Index (RSI) is to track how fast people are buying or selling Larimar, making its price go up or down.

Oversold Vs Overbought

65

 
Oversold
 
Overbought
The successful prediction of Larimar Therapeutics' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Larimar Therapeutics and does not consider all of the tangible or intangible factors available from Larimar Therapeutics' fundamental data. We analyze noise-free headlines and recent hype associated with Larimar Therapeutics, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting Larimar Therapeutics' stock price prediction:
EPS Estimate Next Quarter
(0.40)
EPS Estimate Current Year
(1.24)
EPS Estimate Next Year
(1.62)
Wall Street Target Price
21.0327
EPS Estimate Current Quarter
(0.37)
Using Larimar Therapeutics hype-based prediction, you can estimate the value of Larimar Therapeutics from the perspective of Larimar Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Larimar Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Larimar because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Larimar Therapeutics after-hype prediction price

    
  USD 6.03  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Larimar Therapeutics Basic Forecasting Models to cross-verify your projections.
To learn how to invest in Larimar Stock, please use our How to Invest in Larimar Therapeutics guide.
Intrinsic
Valuation
LowRealHigh
2.027.6213.22
Details
Naive
Forecast
LowNextHigh
0.115.2910.89
Details
11 Analysts
Consensus
LowTargetHigh
11.2712.3813.74
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.55-0.41-0.32
Details

Larimar Therapeutics After-Hype Price Prediction Density Analysis

As far as predicting the price of Larimar Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Larimar Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Larimar Therapeutics, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Larimar Therapeutics Estimiated After-Hype Price Volatility

In the context of predicting Larimar Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Larimar Therapeutics' historical news coverage. Larimar Therapeutics' after-hype downside and upside margins for the prediction period are 0.43 and 11.63, respectively. We have considered Larimar Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
6.16
6.03
After-hype Price
11.63
Upside
Larimar Therapeutics is moderately volatile at this time. Analysis and calculation of next after-hype price of Larimar Therapeutics is based on 3 months time horizon.

Larimar Therapeutics Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Larimar Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Larimar Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Larimar Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.27 
5.60
  0.13 
  0.20 
9 Events / Month
14 Events / Month
In about 9 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
6.16
6.03
2.11 
1,143  
Notes

Larimar Therapeutics Hype Timeline

Larimar Therapeutics is now traded for 6.16. The entity has historical hype elasticity of -0.13, and average elasticity to hype of competition of -0.2. Larimar is expected to decline in value after the next headline, with the price expected to drop to 6.03. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -2.11%, whereas the daily expected return is now at -0.27%. The volatility of related hype on Larimar Therapeutics is about 757.27%, with the expected price after the next announcement by competition of 5.96. About 99.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.98. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Larimar Therapeutics recorded a loss per share of 1.15. The entity last dividend was issued on the 29th of May 2020. The firm had 1:12 split on the 29th of May 2020. Given the investment horizon of 90 days the next expected press release will be in about 9 days.
Check out Larimar Therapeutics Basic Forecasting Models to cross-verify your projections.
To learn how to invest in Larimar Stock, please use our How to Invest in Larimar Therapeutics guide.

Larimar Therapeutics Related Hype Analysis

Having access to credible news sources related to Larimar Therapeutics' direct competition is more important than ever and may enhance your ability to predict Larimar Therapeutics' future price movements. Getting to know how Larimar Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Larimar Therapeutics may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
PCVXVaxcyte(10.51)10 per month 2.19  0.03  3.16 (4.09) 42.81 
SNDXSyndax Pharmaceuticals(0.06)10 per month 0.00 (0.1) 4.02 (4.33) 34.00 
MRUSMerus BV(1.93)8 per month 0.00 (0.17) 3.08 (2.83) 10.85 
STROSutro Biopharma 0.13 5 per month 0.00 (0.17) 8.38 (8.71) 30.73 
IMRXImmuneering Corp(0.36)6 per month 5.21  0.13  15.50 (8.68) 60.06 
CNTACentessa Pharmaceuticals PLC 0.32 9 per month 3.06  0.11  8.37 (5.69) 21.09 
CELCCelcuity LLC(0.36)7 per month 0.00 (0.16) 4.02 (5.73) 16.97 
IKNAIkena Oncology(0.05)4 per month 1.39 (0.07) 1.81 (1.74) 13.50 
SPROSpero Therapeutics 0.01 9 per month 0.00 (0.13) 3.79 (4.58) 14.92 
BOLTBolt Biotherapeutics 0.03 8 per month 0.00 (0.15) 4.76 (4.48) 14.96 
CHRSCoherus BioSciences(0.03)5 per month 0.00 (0.04) 7.62 (6.94) 34.15 
GRCLGracell Biotechnologies 0.00 0 per month 6.35  0.16  16.34 (6.25) 52.11 
NLTXNeoleukin Therapeutics(0.14)1 per month 0.00 (0.08) 4.05 (3.53) 27.84 
SRZNSurrozen(0.75)5 per month 4.86  0.05  16.74 (7.91) 33.59 
KROSKeros Therapeutics(0.79)9 per month 2.13  0.09  4.39 (4.31) 16.94 
KZRKezar Life Sciences(0.20)7 per month 3.01  0.06  8.11 (4.39) 51.13 
CABACabaletta Bio(0.42)6 per month 0.00 (0.26) 7.82 (10.89) 30.64 
FIXXHomology Medicines(0.01)2 per month 3.52  0.01  5.77 (5.61) 19.43 
DAWNDay One Biopharmaceuticals 0.23 9 per month 2.72 (0.04) 3.84 (3.69) 11.44 
ALECAlector 0.1 8 per month 0.00 (0.07) 8.66 (7.89) 26.60 

Larimar Therapeutics Additional Predictive Modules

Most predictive techniques to examine Larimar price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Larimar using various technical indicators. When you analyze Larimar charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Larimar Therapeutics Predictive Indicators

The successful prediction of Larimar Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Larimar Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Larimar Therapeutics based on analysis of Larimar Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Larimar Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Larimar Therapeutics's related companies.
 2021 2022 2023 2024 (projected)
Current Ratio8.1611.289.4911.63
Net Debt To EBITDA1.280.610.510.78

Story Coverage note for Larimar Therapeutics

The number of cover stories for Larimar Therapeutics depends on current market conditions and Larimar Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Larimar Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Larimar Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Larimar Therapeutics Short Properties

Larimar Therapeutics' future price predictability will typically decrease when Larimar Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Larimar Therapeutics often depends not only on the future outlook of the potential Larimar Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Larimar Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding43.9 M
Cash And Short Term Investments86.8 M

Additional Tools for Larimar Stock Analysis

When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.